Metformin in obesity, cancer and aging: Addressing controversies

Aging

Volumn 4, Issue 5, 2012, Pages 320-329

  Berstein, Lev M ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

Aging; Cancer; Metformin; Modifying factors; Obesity

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN;

AGING; ANIMAL; BODY WEIGHT; DRUG EFFECT; FEMALE; HUMAN; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; REVIEW;

AGING; ANIMALS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS; OBESITY; OXIDATIVE STRESS; POLYCYSTIC OVARY SYNDROME;

EID: 84864541430     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100455     Document Type: Review

References (98)

1. Tannenbaum A, and Silverstone H. Nutrition in relation to cancer. Adv Cancer Res. 1953; 1: 451-501.
2. Lew EA, and Garfinkel L. Variations in mortality by weight among 750000 men and women. J. Chronic Dis 1979; 32: 563-576.
3. Dilman V.M. Development, Aging and Disease. A New Rationale for an Intervention Strategy.-Chur: Harwood Academic Publ., 1994; 387 p.
4. Calle E.E., and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews Cancer. 2004; 4: 579-591.
5. Giovannucci E., Harlan D.M., Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, and Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33: 1674-1685.
6. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. CA Cancer J. Clin. 2004; 54: 190-207.
7. Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. Aging (Albany NY). 2009; 1:281-288.
8. Lugaro G, Giannattasio G, Torti G, and Perani G. Studies on the antitumoral activity of the biguanides. V. Arch Ital Patol Clin Tumori. 1967; 10:211-222. 9. Roginsky M.S., and Sandler J. Phenformin in human obesity. Ann N Y Acad Sci. 1968; 148: 892-896.
9. Roginsky M.S., and Sandler J. Phenformin in human obesity. Ann N Y Acad Sci. 1968; 148: 892-896.
10. Dilman VM, Berstein LM, Yevtushenko TP, Tsyrlina YV, Ostroumova MN, Bobrov YuF, Revskoy SYu, Kovalenko IG, and Simonov NN. Preliminary evidence on metabolic rehabilitation of cancer patients. Arch Geschwulstforsch. 1988; 58: 175-183.
11. Pedersen J. The effect of metformin on weight loss in obesity. Acta endocrinol. (Copenh.). 1965; 49: 479-486.
12. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, and Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330: 1304-1305.
13. Goodwin PJ, and Stambolic V. Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin. Breast. 2011. Suppl 3: S31-35.
14. Dilman VM. Age-associated elevation of hypothalamic, threshold to feedback control, and its role in development, ageing, and disease. Lancet. 1971; 1:1211-1219.
15. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget. 2011; 2:1352-1367.
16. Anisimov VN, Sikora E, and Pawelec G. Relationships between cancer and aging: a multilevel approach. Biogerontology. 2009; 10: 323-338.
17. Becker S, Dossus L, and Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem. 2009; 115: 86-96.
18. Levri K.M., Slaymaker E., Last A, Yeh J, Ference J, D'Amico F, and Wilson SA. Metformin as Treatment for Overweight and Obese Adults: A Systematic Review. Ann Fam Med. 2005; 3: 457-461.
19. Leblanc E.S., O'Connor E., Whitlock E.P., Patnode CD, and Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011; 155: 434-447.
20. Salpeter SR, Buckley NS, Kahn JA, and Salpeter EE. Metaanalysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008; 121: 149-157.
21. Meneghini LF, Orozco-Beltran D, Khunti K, Caputo S, Damçi T, Liebl A, and Ross SA. Weight beneficial treatments for type 2 diabetes. J. Clin. Endocrinol. Metab. 2011; 96: 3337-3353.
22. Bruno RV, de Avila MA, Neves FB, Nardi AE, Crespo CM, and Sobrinho AT. Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference. Fertil Steril. 2007; 88: 510-512.
23. Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, and Norman RJ. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum Reprod Update. 2009; 15: 57-68.
24. Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M, Sebring NG, Reynolds JC, Brady SM, and Calis KA. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes. 2011; 60: 477-485.
25. Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, Ward GM, and Cowell CT. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006; 91: 2074-2080.
26. Moreno-Navarrete J.M., Ortega F.J., Rodríguez-Hermosa J.I, Sabater M, Pardo G, Ricart W, and Fernández-Real JM. OCT1 expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes. 2011; 60: 168-176.
27. Delahanty LM, Pan Q, Jablonski KA, Watson KE, McCaffery JM, Shuldiner A, Kahn SE, Knowler WC, Florez JC, Franks PW; for the Diabetes Prevention Program Research Group. Genetic Predictors of Weight Loss and Weight Regain After Intensive Lifestyle Modification, Metformin Treatment, or Standard Care in the Diabetes Prevention Program. Diabetes Care. -2011 Dec 16. [Epub ahead of print]
28. Vincent HK, and Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond). 2006; 30: 400-418.
29. Chakraborty A, Chowdhury S, and Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract. 2011; 93(1):56-62.
30. Anedda A, Rial E, and González-Barroso MM. Metformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 levels. J Endocrinol. 2008; 199: 33-40.
31. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, and Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab. 2004; 89:2569-2575.
32. Shin MJ, Hyun YJ, Kim OY, Kim JY, Jang Y, and Lee JH. Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes (Lond). 2006; 30: 1529-1534.
33. Després JP. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab. 2003; 29(4 Pt 2): 6S53-6S61.
34. Nobes JP, Langley SE, Klopper T, Russell-Jones D, and Laing RW. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2011 Sep 20. [Epub ahead of print]
35. Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E, and Grassi G. Cancer mortality reduction and metformin. A retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab. 2011 Aug 3. [Epub ahead of print].
36. Berstein L.M. Biguanides: An expansion to Practical Oncology (past and present). St.Petersburg, Aesculap, 2010, 144p.
37. Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, and Kip KE. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011; 34: 2323-2328.
38. Bodmer M, Becker C, Meier C, Jick SS, and Meier CR. Use of Metformin Is Not Associated with a Decreased Risk of Colorectal Cancer: A Case-Control Analysis. Cancer Epidemiol Biomarkers Prev. 2012 Jan 20. [Epub ahead of print]
39. Azoulay L, Dell'Aniello S, Gagnon B, Pollak M, and Suissa S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev. 2011; 20: 337-344.
40. Bosco JL, Antonsen S, Sørensen HT, Pedersen L, and Lash TL. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev. 2011; 20: 101-111.
41. Currie CJ, Poole CD, and Gale EA. The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52:1766-1777.
42. Oliveria SA, Koro CE, Yood MU, and Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metabol. Syndrome: Clin. Res. & Reviews. 2008; 2: 47-57.
43. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, and Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011; 11: 20.
44. METFORMIN TRIALLISTS' COLLABORATION, Stevens R, McLellan J, Cairns B., Ali R, Bankhead C, Bethel A, Crowe F, Farmer A, Harrison S, Hirst J, Perera R, Pluddemann A, Rose P, Home P, Kahn S. et al. Cancer and all-cause mortality: metaanalysis of randomized clinical trials of metformin. Amer. Diab. Assoc. (ADA) Meeting 2011.Abstr. 0950-P.
45. Wild SH. Diabetes, treatments for diabetes and their effect on cancer incidence and mortality: attempts to disentangle the web of associations. Diabetologia. 2011; 54:1589-1592
46. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G; ADOPT Study Group; RECORD Steering Committee. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (ADiabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia. 2010; 53: 1838-1845.
47. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, and Stricker BH. Lower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea Derivatives: Results from a large population-based follow-up study. Diabetes Care. 2012: 35: 119-124.
48. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, and Gonzalez-Angulo AM. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2011 Jul 28. [Epub ahead of print]
49. Patel T, Kirby W, Hruby G, Benson MC, McKiernan JM, and Badani K. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology. 2010; 76: 1240-1244.
50. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, and Morgan CL. Mortality After Incident Cancer in People With and Without Type 2 Diabetes: Impact of metformin on survival. Diabetes Care. 2012; 35: 299-304.
51. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, and Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2011 Sep 12. [Epub ahead of print]
52. Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, and Lengyel E. Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity. Obstet Gynecol. 2012; 119: 61-67.
53. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila). 2010; 3: 1060-1065.
54. Dilman VM, Berstein LM, Ostroumova MN, Fedorov SN, Poroshina TE, Tsyrlina EV, Buslaeva VP, Semiglazov VF, Seleznev IK,Bobrov YuF, Vasilyeva IA, Kondratjev VB, Nemirovsky VS, and Nikiforov YF. Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology. 1982; 39:13-19.
55. Berstein LM. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond. Future Oncol. 2010; 6: 1313-1323.
56. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, Moulder-ThompsonS, Dewar JA, and Thompson AM. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat. 2011; 128: 783-794.
57. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nakagama H, and Nakajima A. Metformin suppresses colorectal aberrant crypt foci in a shortterm clinical trial. Cancer Prev Res (Phila). 2010; 3: 1077-1083.
58. Bershtein L.M., Maximov S.Ya., Danilova M.A., Gershfeld E.D., Boyarkina M.P., Hadzhimba A.S., Kovalevskiy A.Yu., Turkevich E.A., and Meshkova I.E. Comparison of aromatase and metformin neoadjuvant effects in endometrial cancer patients. Vopr. Onkol. 2011; 57: 737-741.
59. Editorial. Cancer prevention with a diabetes pill? Science. 2012; 335: 29.
60. Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel PS, Comin-Anduix B, and Ribas A. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011; 9:76.
61. Zhuang Y, and Miskimins WK. Metformin induces both caspase-dependent and poly(ADP-ribose) polymerasedependent cell death in breast cancer cells. Mol Cancer Res. 2011; 9: 603-615.
62. Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, and Ieiri I. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet. 2007; 52:117-122.
63. Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, and Brosen K. The pharmacogenetics of metformin and its impact on plasma metforminsteady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011; 21: 837-850.
64. GoDARTS and UKPDS Diabetes Pharmacogene-tics Study Group; Wellcome Trust Case Control Consortium 2, Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ, Burch L, Carr F, Strange A, and Freeman C. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2011; 43: 117-120.
65. Abbatecola AM, Paolisso G, Corsonello A, Bustacchini S, and Lattanzio F. Antidiabetic oral treatment in older people: does frailty matter? Drugs Aging. 2009; Suppl 1:53-62.
66. Salpeter SR, Greyber E, Pasternak GA, and Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010. 14: CD002967.
67. Holman R. Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ. Annu Diabetol Hotel Dieu. 2007: 13-20.
68. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, and Elliott P. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009; 339: b4731.
69. Blagosklonny MV, and Campisi J. Cancer and aging: more puzzles, more promises? Cell Cycle. 2008; 7: 2615-2618.
70. Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY). 2010; 2: 760-774.
71. Bulterijs S. Metformin as a geroprotector. Rejuvenation Res. 2011; 14: 469-482.
72. Dilman VM. Ageing, metabolic immunodepression and carcinogenesis. Mech Ageing Dev. 1978; 8: 153-173.
73. Menendez JA, Cufí S, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Vellon L, and Vazquez-Martin A. Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer. Aging (Albany NY). 2011; 3: 1063-1077.
74. Oliveras-Ferraros C, Vazquez-Martin A, and Menendez JA. Pharmacological mimicking of caloric restriction elicits epigenetic reprogramming of differentiated cells to stem-like self-renewal states. Rejuvenation Res. 2010; 13519-526.
75. Arkad'eva AV, Mamonov AA, Popovich IG, Anisimov VN, Mikhel'son VM, and Spivak IM. Metformin slows down ageing processes at the cellular level in SHR mice. Tsitologiia. 2011; 53166-174.
76. Halicka HD, Zhao H, Li J, Traganos F, Zhang S, Lee M, and Darzynkiewicz Z. Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling. Aging (Albany NY). 2011; 3: 1028-1038.
77. Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY). 2011; 3: 1130-1141.
78. Onken B, and Driscoll M. Metformin Induces a Dietary Restriction-Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One 2010; 5: e8758.
79. Ma TC, Buescher JL, Oatis B, Funk JA, Nash AJ, Carrier RL, and Hoyt KR. Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci Lett. 2007; 411: 98-103.
80. Spindler SR. Review of the literature and suggestions for the design of rodent survival studies for the identification of compounds that increase health and life span. Age (Dordr). 2012; 34: 111-20.
81. Pianka E.R. On r and K selection. American Naturalist 1970; 104 : 592-597.
82. Golubev AG. Biochemistry of lifespan extension. Adv Gerontol. 2003; 12: 57-76.
83. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, and Franceschi C. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol. 2005; 40: 685-693.
84. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, Karkach AS, and Romanyukha AA. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle. 2010; 9: 188-197.
85. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MV, Kovalenko IG, Poroshina TE, and Semenchenko AV. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008; 7: 2769-2773.
86. Yurova M.N. Effect of plastochinone derivative on spontaneous carcinogenesis and life span in mice. Candidate Thesis. 2011, SPb, 160pp.
87. Anisimov VN, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Egormin PA, Yurova MV, Rosenfeld SV, Semenchenko AV, Kovalenko IG, Poroshina TE, and BersteinLM. Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging (Albany NY). 2010; 2: 945-958.
88. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Kovalenko IG, and Poroshina TE. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY). 2011; 3: 148-157.
89. Smith DL Jr, Elam CF Jr, Mattison JA, Lane MA, Roth GS, Ingram DK, and Allison DB. Metformin supplementation and life span in Fischer-344 rats. J Gerontol A Biol Sci Med Sci. 2010; 65:468-474.
90. Blagosklonny MV. Metformin and sex: Why suppression of aging may be harmful to young male mice. Aging (Albany NY). 2010; 2: 897-899.
91. Berstein LM. Newborn macrosomy and cancer. Adv Cancer Res. 1988; 50: 231-78.
92. Mercken EM, Carboneau BA, Krzysik-Walker SM, and de Cabo R. Of mice and men: The benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev. 2011 Dec 20. [Epub ahead of print]
93. Smith DL Jr, Nagy TR, and Allison DB. Calorie restriction: what recent results suggest for the future of ageing research. Eur J Clin Invest. 201040: 440-450.
94. Spindler SR, and Mote PL. Screening candidate longevity therapeutics using gene-expression arrays. Gerontology. 2007; 53(5): 306-321.
95. Chong CR, and Chabner BA. Mysterious metformin. Oncologist. 2009; 14: 1178-1181.
96. Segal ED, Yasmeen A, Beauchamp MC, Rosenblatt J, Pollak M, and Gotlieb WH. Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochem Biophys Res Commun. -2011 Oct 2. [Epub ahead of print]
97. Dilman VM, and Anisimov VN. Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice. Gerontology. 1980; 26: 241-246.
98. Golubev AG. The issue of feasibility of a general theory of aging. III. The theory and practice of aging. Adv Gerontol. 200922:387-400.